ArticleJournal of dental sciences2026
Establishment of diagnostic markers for differentiation of oral lichen planus and oral erythroleukoplakia with lichenoid features through a transcriptomic profile analysis.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Oral lichen planus (OLP) frequently overlaps clinically and histopathologically with oral erythroleukoplakia (OEL), a high-risk oral potentially malignant disorder. OEL with lichenoid features (OEL-L) may closely mimic OLP, resulting in diagnostic uncertainty and inappropriate management. This study aimed to characterize immune and epithelial transcriptomic differences between OLP and OEL-L and to identify potential diagnostic biomarkers. Materials and methods: Formalin-fixed paraffin-embedded specimens from 6 OLP and 6 OEL-L cases were analyzed retrospectively. Diagnoses were established according to World Health Organization criteria. Immune and epithelial gene expression profiles were assessed using the NanoString nCounter Autoimmune Discovery and PanCancer Progression panels. Differentially expressed genes were identified using a fold change >5 and Results: OLP lesions showed marked activation of T-cell-associated immune pathways, including T-cell receptor signaling, natural killer cell cytotoxicity, and type I interferon responses. In contrast, OEL-L exhibited global suppression of adaptive immune signatures with enrichment of metabolic and oxidative stress pathways. OEL-L demonstrated increased expression of B-cell- and plasma cell-related genes [tumor necrotic factor receptor superfamily member 17 (TNFRSF17), CD79A] and epithelial-derived C-X-C motif ligand 8 (CXCL8) and matrix metalloproteinase 12 (MMP12), accompanied by stromal and extracellular matrix-remodeling signatures. Conclusion: Distinct immune and epithelial transcriptomic profiles differentiate OLP from OEL-L. CXCL8, MMP12, and B-cell-associated markers may serve as useful adjunctive biomarkers for pathological discrimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.